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Given the high prevalence of chronic obstructive pulmonary disease (COPD), the impact of
exacerbations on quality of life, and the costs incurred, effective ways for the prevention
of exacerbations, and for reductions in the severity and duration of COPD symptoms are
needed. Bacterial immunostimulation has been advocated as a management strategy in
COPD for the purposes of preventing acute exacerbations. In particular, it suggests that the
use of oral multicomponent vaccines may reduce the severity and duration of acute
episodes. The way in which bacterial extracts may exert their effects is not fully
understood although a number of possible specific mechanisms have been suggested. Given
the high prevalence of COPD worldwide and the high cost of acute exacerbations, some
cost-effectiveness analyses suggest that bacterial immunostimulants may become a key
element in the improved control of this condition. Nonetheless, larger and longer clinical
trials are needed to investigate efficacy before oral vaccination could be recommended as
part of the routine clinical management of COPD, mainly in advanced COPD. It remains also
to be investigated whether this protective effect may be additive to the other treatments.
In any case, it is well known that for Streptococcus pneumoniae, non-typable Haemophilus
influenzae and Moraxella catarrhalis, recurrent infections occur because of strain
heterogeneity. Therefore, a single or even multiple strain vaccine with a killed whole
cell formulation is possibly not the ideal vaccine. Moreover, the method of inactivation can
affect the immunogenicity of essential antigens through denaturation. For this reason, the
efficacy of bacterial immunostimulants should not only be assessed but also compared.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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It is now recognized that exacerbation frequency is an
important outcome in chronic obstructive pulmonary disease
(COPD) as patients prone to frequent exacerbations have
impaired health status, reduced physical activity, increased
lower airway bacterial colonization and a faster decline in lung
function.1 The frequency of exacerbations increases with the
severity of COPD, but the mechanisms modulating exacerba-
tion frequency in patients with COPD are largely unknown.
Although infection clearly has the ability to induce airway
inflammation, the role that bacteria play in COPD exacerba-
tions remains controversial.2 Nonetheless, COPD exacerbation
could be precipitated by an increase in bacterial number,
change in the airway compartment in which bacteria are
located, or acquisition of new, more virulent, and/or more
proinflammatory bacterial species or strain.3 Several recent
studies have shown a clear association between the isolation
of bacterial species such as Streptococcus pneumoniae,
Moraxella catarrhalis, and Haemophilus influenzae and acute
exacerbation.4 The underlying aetiology of the exacerbation
may affect FEV1 decline. For example, Wilkinson et al.
5
described the greatest reduction in FEV1 (56ml in 1 year) in
patients with a higher airway bacterial load, and this decline
was greater still in patients with a change in bacteria as
opposed to a single colonizing species.
Given the high prevalence of COPD, the impact of
exacerbations on quality of life, and the costs incurred,
effective ways for the prevention of exacerbations, and for
reductions in the severity and duration of COPD symptoms
are needed.6
Smoking cessation, vaccination against influenza and
pneumococcal pneumonia, antibiotic therapy, and a short
course of systemic corticosteroids are the most important
strategies to prevent and control exacerbations.7 The Global
Initiative for Chronic Obstructive Lung Disease (GOLD)8 also
recommended long-term therapy with inhaled corticoster-
oids for patients with moderate-to-severe COPD who were
experiencing recurring exacerbations but more recent
evidence from trials combining inhaled corticosteroids and
long-acting inhaled b2-agonists shows a significant additional
effect on pulmonary function and a reduction in symptoms
in those receiving combination therapy compared with its
components.9 Potentially interesting alternative strategies
for an improved control of symptoms and exacerbations in
COPD include the use of mucolytic, antioxidant, and
immunomodulator agents, defined as medications thatproduce an enhancement of non-specific immunity and an
increased infection resistance.
Bacterial immunostimulation has been advocated as a
management strategy in COPD for the purposes of prevent-
ing acute exacerbations. Some previous data10 showed some
interesting synergic effects of bacterial extracts in extend-
ing the immunological response to influenza vaccine in COPD
patients. Thinking of influenza as one of most important risk
factor in COPD exacerbations, this could be an interesting
clinical outcome. It is not surprising, therefore, that use of
bacterial immunostimulants is an option included in the
management recommendation of some guidelines.11 Inacti-
vated microorganisms offer certain advantages as a poten-
tial vaccine for mucosal immunization. They are naturally
occurring microparticles, which possess multiple antigens
and are relatively inexpensive to produce. These immuno-
modulatory bacterial extracts are commonly administered
by the oral route.Mechanisms of action of bacterial
immunostimulants
The way in which bacterial extracts may exert their effects is
not fully understood. It has been suggested that bacterial
immunostimulants, either killed whole cell formulations or
agents containing antigens derived from several strains of
bacteria, may increase resistance to infection by these
organisms. They might exert their effects on lung defences
by specific cell trafficking through the common mucosal
immune system.12 In animal models, recognition of the orally
administered bacteria by gut-associated lymphoid tissue (the
Peyer’s patches in particular) is followed by trafficking of
intestinally derived B- and T-cells to bronchus-associated
lymphoid tissue, and this might lead to an immune response
against these pathogens in the respiratory tract.13
A number of possible specific mechanisms have been
suggested. In vivo and in vitro studies in animals and humans
have shown that the action of these extracts is based on
the modulation of the host immune response, and it has
been found to upregulate interferon g (IFN-g) and inter-
leukin (IL)-2, IL-6, and IL-8. IFN-g plays a pivotal role in the
body defence under circumstances of respiratory exposure
to microorganism. CD4T cells cooperate with phagocytic
cells to increase their antimicrobial effector capabilities via
the secretion of IFN-g.14 CD8 T-cells also use IFN-g as an
antiviral effector moiety.15–17 It has been documented that
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and CD8 subsets in COPD patients, compared to non-smoker
and ex-smoker healthy control subjects.18
In vitro bacterial extracts exert immunomodulatory
action via modulation of the signal transducer gp130 and
gp130 binding cytokines, including IL-6 and IL-11.19 The
increase of IL-6, which plays a protective role in attenuating
acute inflammatory responses, and IL-11, which together
with IL-6 protects animals from mortality in a bacterial-
induced toxic shock model,20 may explain enhanced T- and
B-cell activity, immunoglobulin synthesis, and IgM to IgG
switch.19
Other studies in experimental models have confirmed that
bacterial extracts elicit long-lasting specific serum immu-
noglobulin (Ig) G antibody response.21 This is an important
finding because adults with recurrent respiratory infections
frequently have some variant of IgG deficiency, often
associated with a functional impairment of specific antibody
response.22 Assessment of IgG subclasses has shown a
balanced pattern of IgG1–IgG2a responses, which indicates
more balanced Th1–Th2 environment within the lungs.21
In addition, bacterial extracts also elicit the production of
specific anti-bacterial secretory IgA (sIgA) in BAL.21 Inter-
estingly, a major role of local sIgA in mucosal defence
against invading pathogens has long been clearly demon-
strated.23 These antibodies have special features in the
salivary fluid: for example, they have the capacity of
opsonizing bacterial bodies, thus allowing their phagocytosis
and subsequent killing.13 IgA are thus the main antibody
isotype of mucosal secretions: they account for the first
defence line against both bacterial and viral infections
because of their activity against antigens recognized with
high specificity and other antigens recognized with low
specificity.24
It seems to be intriguing that bacterial extracts have been
shown to upregulate the activity, phagocytosis, and antigen
presentation of macrophages, and to increase the capacity
of the body to eliminate the invading pathogens.25 More-
over, they also activate bacterial killing by polymorpho-
nuclear cells in mice and rabbits, thus enhancing the
clearance of bacteria from the blood.26 It has also
been documented that an immunostimulating agent that
includes material from eight different species of bacteria
(S. pneumoniae, H. influenzae, Klebsiella pneumoniae,
Klebsiella ozaenae, Staphylococcus aureus, Streptococcus
pyogenes, Streptococcus viridans and M. catarrhalis) that
are frequently present in the lower respiratory tract, induces
upregulation of adhesion molecule expression at the surface
of phagocytes through CD14-independent pathways.27
An analysis of pre- and post-therapeutic bronchoalveolar
lavage (BAL) fluid of 28 adult patients with non-obstructive
chronic bronchitis revealed that this immunostimulating
agent increased the CD4+/CD8+ lymphocyte ratio and IFN-g
levels. Furthermore, the alveolar macrophage activity was
normalized and the BAL IgA was moderately increased.Contrasting conclusions on the effect of
bacterial immunostimulants on exacerbations
Unfortunately, the evidence in favour of the use of bacterial
immunostimulants is available only from a limited body ofdata. An earlier meta-analysis suggested that these drugs
may have an effect on exacerbations, but the trial quality is
poor.6 A latest systematic review of OM-85 BV (Broncho-
vaxoms) to evaluate its efficacy and safety in COPD and
chronic bronchitis has confirmed that consistent evidence
across multiple important outcomes does not exist to clearly
demonstrate clinical benefit of this agent.28 Thirteen trials
involving 2066 individuals were examined. Utilizing quanti-
tative pooled analysis in these studies, with one or more
acute exacerbations as the endpoint, the authors have found
a non-statistically significant trend in favour of OM-85 BV
[relative risk 0.83, 95% confidence interval 0.65–1.05]. Ten
trials enrolled a heterogeneous population with chronic
bronchitis. In these trials, exacerbation rates were less with
OM-85 BV in four of the nine trials reporting this outcome.
Varied results in the outcomes of hospitalization, symptom
scores, and antibiotic or steroid use were found across
studies. Withdrawals and adverse events were similar
between OM-85 BV and placebo.
Nonetheless, a placebo-controlled study,29 which investi-
gated 350 nursing home residents aged X65 years with
chronic bronchitis, found a significant reduction of acute
bronchitis in patients in whom a mixed bacterial extract had
been used (28% reduction in the number of lower respiratory
tract infections, 40% reduction in the number of episodes of
acute bronchitis, and 28% reduction in the number of
antibiotic prescriptions). On the contrary, the Canadian
study of Collet et al.,30 a double-blind placebo-controlled
randomized clinical trial that has recruited 381 patients
(n ¼ 190 in OM-85 BV versus n ¼ 191 in placebo) and
followed them up for 6 months, found no differences
regarding the frequency of acute exacerbations, but it
documented a significant reduction in the total number
of days hospitalized (OM-85 BV for 287 days versus placebo
for 642 days).
A more recent trial,31 which has been performed in China
and has enrolled 90 patients with chronic bronchitis
complicated with COPD, has documented a significant
decrease in the incidence, duration, and severity of acute
exacerbation, as well as a reduction in the course of
antibiotics administered and in the dosage of bronchodilator
and mucolytic agent in the group of patients that has been
treated with 7mg OM-85 BV daily for the first 10 days of each
month for 3 consecutive months, as compared to the group
that has received placebo. Symptom scores for cough,
sputum, dyspnoea, as well as symptoms observed upon
auscultation of the chest also improved significantly in group
OM-85 BV as compared to group placebo. The bacterial
clearance rate in sputum cultures from patients who
received no antibiotics for the first 3 months was also
significantly higher in group OM-85 BV compared to group
placebo.
A short time ago, Sole`r et al.32 have published a double-
blind multi-centre Swiss–German study that aimed to
demonstrate the protective effect of OM-85 against recur-
rent bronchitic exacerbations in patients with chronic
bronchitis or mild COPD. They enrolled adult outpatients
440 years old of both sexes. The treatment consisted of one
capsule of OM-85 BV or placebo per day for 30 days, followed
by three 10-day courses for months 3, 4 and 5, with a
6-month study duration and monthly control visits. One
hundred and forty-two patients were treated with OM-85 BV
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period, the mean number of acute exacerbations in the OM-
85 BV group was 0.61 per patient versus 0.86 per patient in
the placebo group (29%). The difference between treat-
ments was most notable in patients with a history of current
or past smoking (40%). No serious adverse events were
attributed to the medication and no significant laboratory
changes were reported.
The economic impact of bacterial
immunostimulants in the prevention of
exacerbations
Although all the experimental and clinical findings suggest
the possibility of treating a patient suffering from COPD with
bacterial extracts in order to prevent exacerbations, the
recent guidelines of European Respiratory Society and
European Society for Clinical Microbiology and Infectious
Diseases do not recommend the use of bacterial extracts in
patients with chronic bronchitis or COPD.33 This thought fits
with the Cochrane review of Arandjus et al.,34 which has
concluded that the evidence on the use of bacterial extracts
to prevent exacerbations is inconclusive, although it
suggests that the use of oral multicomponent vaccines may
reduce the severity and duration of acute episodes.
This last point raises the question on the convenience of
using bacterial immunostimulants. A cost-effectiveness
analysis has been carried out in Canada to assess the
economic impact of using OM-85 BV to prevent severe acute
exacerbations in patients with COPD.35 The median cost to
prevent 1 day of hospitalization for a respiratory condition
was CDN$45, with a 95% CI of CDN$18–210. Bootstrap of the
study population and sensitivity analyses showed that the
results were robust and not likely due to random fluctuation;
98.8% of the cost effectiveness and 96.8% of the cost–benefit
ratios favoured the use of OM-85 BV. Indirect costs, defined
as a need for help, were reduced by 36% in the group treated
with OM-85 BV: 779 h of help compared with 1212 h in the
placebo group. This trend, while not significant, is consis-
tent with other results and suggests a decrease in the
severity of exacerbations in the OM-85 BV-treated group.
Also an Italian cost-effectiveness analysis of the use of OM-
85 BV in chronic bronchitic patients showed favourable
economic impact of this treatment.36 Although the treat-
ment caused only a mean value of 0.6 which prevented
acute exacerbations per 6 months per patient, and a
reduction of 9 days in antibiotic treatment per 6 months
per patient, and this could be considered a critical
parameter, these reductions involved a reduction in cost of
86,075 Lira. Considering that at the time of the study the
additional costs for the preventive treatment with OM-85
BV, based on prices for Italy, were 34,980 Lira per patient
per 6 months, the effective cost savings per patient per
6 months were 51,095 Lira. Even assuming 0.3 prevented
exacerbations per 6 months per patient, the preventive
treatment still proved to be cost effective.
Although not focussed on cost-effectiveness analysis, the
Sole`r et al.’s trial32 has documented that the reduction in
bronchitic exacerbations led to a reduction in the number of
consultations of 2.2 per 10 patients and 6 months, with the
corresponding diagnostic workup and treatment costs.Bacterial immunostimulants apart from OM-85
BV
Ismigens is a polyvalent mechanical bacterial lysate (PMBL)
prepared by bacteria (S. aureus, S. pyogenes, S. viridans,
K. ozaenae, H. influenzae serotype B, M. catarrhalis, and
S. pneumoniae) obtained by mechanical lysis. The mechan-
ical method is particularly efficient in that is achieves lysis
of 80–100% of the bacteria. What is even more interesting,
compared with other methods of lysis (such as alkaline lysis
which brings about fragmentation significant enough to
cause loss of immunogenicity), mechanical lysis does not
alter the structure of the antigens: this ensures a prepara-
tion having excellent antigenic properties. The lysate thus
induces a specific immuno-stimulation against the seven
bacterial strains composing it, selected from among those
most often responsible for respiratory infections. According
to extensive and well-established literature, PMBL treat-
ment seems to yield various beneficial effects, including a
significant increase in antibody titre even after just one
treatment cycle, in terms of IgM, IgG, and IgA.37 This has a
positive therapeutic effect on the amplitude of the
spectrum of immunological production and on the produc-
tion of opsonizing antigens.38 In particular, it has been
suggested that this PMBL exerts a therapeutic and prevent-
ing effect in acute and recurrent infections because it
induces the activation and enhancement of both IgM
memory B lymphocytes (CD24+/CD27+ cells) and IL-2
receptor-expressing lymphocytes (CD25+ cells) involved
either in humoral or cellular immunity.39 Moreover, it is
able to induce a specific immune response in the salivary
fluid of healthy subjects.24 It is important to highlight that
sublingual administration guarantees effective protection of
the respiratory mucosae, which represent the first barrier to
infection, making it possible to bypass the gastroenteric
tract. This avoids denaturing the antigens and puts them
directly in contact with the cells that best carry out the task
of antigen-presenting cells, namely the Langherans cells.37
In an Italian study conducted on 57 patients aged over 75
suffering from chronic obstructive bronchitis and affected
by at least one exacerbation over the past 12 months,
Ismigens significantly reduced the absolute number of
exacerbations, their length and seriousness, as well as the
need to use antibiotic treatments, and the overall cost of
the treatment of these patients during the period of
treatment compared to the same period for the previous
year, during which time no antibacterial prophylaxis had
been administered.40 It should be noted that the mean cost
of the antibiotic therapy during the period from September
to February of the year before the use of Ismigens was
h3459.60, while during the period from September to
February of the year of the trial it was only h1499.40
(57%). Adding the latter amount to the cost of the
prophylactic therapy with Ismigens, equal to h1295.04,
the total cost of h2794.44 was in any case significantly lower
(20%) than the cost for the same period of the previous
year (an extremely important saving for the health structure
management). In another multicentre study, 178 patients
were randomized into two different groups: one group was
treated with Ismigens (first 10 days of each month for 3
consecutive months) and the other with placebo.41 The trial
was double blind. At the end of treatment, patients were
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were seen to be significantly lower in the group treated with
the lysate than in the placebo group. Ismigens treatment
led to a highly significant reduction in the frequency (215
versus 248 cases) and duration (10.6 days versus 15.8 days)
of exacerbations, as well as a decrease in antibiotic
consumption (270 doses) and hospitalization time
(275 days versus 590 days).
Luivacs (LW-50020) is another standardized mixture
of bacterial strains lysats (S. aureus, S. pneumoniae,
S. pyogenes, K. pneumoniae, M. catarrhalis, H. influenzae)
that has been evaluated in the treatment of chronic
bronchitis and COPD.42,43 Apparently, it is efficacious in
treating patients with recurrent respiratory tract infections.
Biostims is composed of K. pneumoniae glycoprotein
extract that, apparently, may impact not only the innate
immune responses but potentially enhance adaptive im-
mune responses by upregulating expression of molecules
involved in antigen presentation on antigen-presenting
cells.44 In a trial that enrolled 40 patients with chronic
bronchitis, it reduced the number and the duration of
infectious exacerbations of chronic bronchitis with respect
to those observed in the corresponding period of the
previous year.45
Ribomunyls contains ribosomal RNA from bacteria caus-
ing recurrent respiratory tract infections together with the
glycoprotein from K. pneumoniae. It seems able to change
the proportions of inflammatory cells present in bronchoal-
veolar lavage of patients with chronic bronchitis.46
It has been documented that in COPD patients, AM3, a
commercially available immunomodulator with a low toxi-
city profile (its active ingredient is a polysaccharide/protein
compound purified from Candida utilis), is able to normalize
deficient effector functions in natural killer and phagocytic
cells, which are involved in the innate immune response.47
What must be done for defining the real
importance bacterial immunostimulants in the
prevention of exacerbations?
Given the high prevalence of COPD worldwide and the high
cost of acute exacerbations, the mentioned cost-effective-
ness analyses suggest that bacterial immunostimulants may
become a key element in the improved control of this
condition. Nonetheless, larger clinical trials are needed to
investigate efficacy before oral vaccination could be
recommended as part of the routine clinical management
of COPD,34,48 mainly in advanced COPD patients, those with
severely impaired lung function and, consequently, at high
risk, and in selected patients with frequent exacerbations. It
remains also to be investigated whether this protective
effect may be additive to the other treatments. As correctly
highlighted by Sole`r,49 considering that the mechanism of
action of bacterial immunostimulants is distinctly different
from that of the inhaled ‘‘standard treatments’’ for COPD,
the question comes up, if the combined use of an effective
inhaled anti-inflammatory regimen and/or bronchodilator
regimen and the immunomodulating oral bacterial immu-
nostimulants might lead to an additive or even better
protection from COPD exacerbations. To give an answer to
this question, more controlled clinical trials with bacterialimmunostimulants in well defined patients with advanced
COPD are needed, where preventing an exacerbation can be
expected to result in the most prominent cost savings and
improvements in quality of life.
It must be highlighted that in most trials, the observation
periods were 6 months and this must be considered a true
bias. As recently stated by the ERS/ATS Task Force on
outcomes in COPD clinical trials,50 trials must last at least 12
months in order to understand the real impact of investiga-
tional treatment. Obviously, each exacerbation should be
classified according to a severity scale.50 In effect, it must
also be stressed that the trials examined in the systematic
review on oral purified extracts in chronic bronchitis and
COPD published by Steurer-Stey et al.6 reported on a large
variety of different end points. It was impossible to combine
outcome data from more than five trials. The main end
point, prevention of exacerbation, was reported in three
trials only, and one of those trials was of limited size and
quality. Further relevant end points that should be examined
in future trial are hospital admission, duration of disease-
free intervals, saved days of absence of work, and the
need for concomitant medications, especially antibiotics
and systemic corticosteroids, as all these factors contribute
to cost.6
In any case, it is well known that for S. pneumoniae, non-
typable H. influenzae and M. catarrhalis, recurrent infec-
tions occur because of strain heterogeneity. Therefore, a
single or even multiple strain vaccine with a killed whole
cell formulation is possibly not the ideal vaccine. Moreover,
the method of inactivation can affect the immunogenicity of
essential antigens through denaturation. For example,
administration of PMBL (Ismigens), i.e. products based on
surface bacterial antigens, whose structure is not denatured
by the use of chemicals, but obtained by simple mechanical
crushing of the pathogens, can lead to a more specific
antibody response to the surface structure of pathogen
bacteria. For this reason, the efficacy of bacterial immu-
nostimulants should not only be assessed but also compared.Conflict of interest statement
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